Illuccix

Gozetotide, the active ingredient in Illuccix, is a drug presented as an intravenous formulation for infusion use. It is currently under clinical investigation and its therapeutic targets are not publicly disclosed.

GNH USA supplies Illuccix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product is manufactured in accordance with EU regulations.

Illuccix (gozetotide) is being evaluated in early‑stage research for potential applications in rare disease therapeutics, but no approved indications have been announced.

No approved indication: No specific therapeutic use has been authorized to date.

Adverse event information for Illuccix (gozetotide) has not been fully published.

Common Side Effects: - No reported common side effects: Data not available. - Mild infusion reaction: Possible transient flushing or warmth. - Transient laboratory changes: Possible temporary alterations in blood counts.

Serious or Rare Side Effects: - No reported serious side effects: Data not available. - Severe hypersensitivity: Potential for anaphylaxis, though unconfirmed. - Organ toxicity: No documented cases, but monitoring is advised.

Because clinical data are limited, careful monitoring is recommended when Illuccix is administered. - Clinical monitoring: Observe patients for any unexpected reactions during and after infusion. - Contraindications: Not recommended for patients with known hypersensitivity to the product. - Pregnancy considerations: Use only if the potential benefit justifies the potential risk; data are lacking. - Breastfeeding: Caution advised; insufficient information on excretion in milk. - Renal/hepatic impairment: Adjustments have not been defined; monitor organ function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Interaction data for gozetotide are limited; clinicians should remain vigilant.

Major Interactions (Avoid): - No known major drug interactions have been identified. - Concomitant use with potent immunosuppressants: Potential additive immunomodulation, monitor closely.

Moderate Interactions (Monitor Closely): - Certain biologics: May alter immune response; assess patient status. - CYP450 substrates: Interaction potential is unclear; observe therapeutic levels. - Anticoagulants: Monitor coagulation parameters if used together.